Enclomiphene Citrate for Secondary Hypogonadism: Off-Label Use, Evidence, and Monitoring

Note: this article is a draft prepared for editorial and qualified medical review. It has not yet received clinician sign-off, and several trial-level claims below are flagged as needing verification against the primary literature before publication.

The trans-isomer enclomiphene is one of two active components in racemic clomiphene (brand name Clomid); the other is the cis-isomer zuclomiphene. As a selective estrogen receptor modulator (SERM), enclomiphene differs chemically from the combination formulation. While clomiphene citrate itself holds FDA approval for ovulation induction in women with ovulatory dysfunction, enclomiphene as a standalone agent has not been approved by the FDA for any use. Administering either formulation to elevate testosterone in men with secondary hypogonadism represents off-label therapy. In the United States, enclomiphene is obtainable exclusively through compounding pharmacies rather than as a manufactured pharmaceutical product bearing FDA approval.

Direct answer: In men with secondary (hypothalamic-pituitary) hypogonadism who want to raise testosterone without suppressing sperm production, enclomiphene works by blocking hypothalamic estrogen receptors, which increases LH and FSH output and drives the testes to make more of their own testosterone. This is mechanistically different from testosterone replacement therapy, which suppresses LH and FSH and commonly reduces sperm counts. Enclomiphene completed manufacturer-sponsored phase III trials but was not approved by the FDA, so its efficacy and safety data, while more substantial than for many compounded hormone products, have not been through full regulatory review, and every prescription today is a compounded, off-label product whose potency and purity depend on the individual pharmacy.

Why this matters: the actual decision most readers face

The useful question for a man with low testosterone and an intact desire for fertility is not "does enclomiphene raise testosterone" but "does it raise testosterone enough, safely enough, and consistently enough from a compounding pharmacy, to be a reasonable alternative to testosterone replacement or to no treatment at all." That question has a more qualified answer than most marketing or forum content suggests, because the compound never reached the regulatory finish line and the compounded product is not standardized.

What secondary hypogonadism means, and why it changes the treatment choice

Secondary hypogonadism refers to low testosterone caused by inadequate signaling from the hypothalamus or pituitary (low or inappropriately normal LH and FSH), rather than testicular failure. Causes include pituitary disease, chronic opioid use, obesity-related suppression, and hypothalamic-pituitary axis suppression following anabolic-androgenic steroid (AAS) use. This last group, men recovering from AAS-induced suppression, is a population where clomiphene-class SERMs have been specifically studied as part of "post-cycle therapy" protocols intended to restart endogenous testosterone production; a 2026 review addresses the mechanisms, efficacy, and diagnostic challenges of using clomiphene citrate for this purpose (Clomiphene Citrate in off-Label Post-Cycle Therapy). That population differs from men with organic secondary hypogonadism unrelated to AAS use, and findings from one group should not be assumed to transfer directly to the other without confirming the diagnosis is truly secondary (intact hypothalamic-pituitary-testicular signaling) rather than primary testicular failure.

Primary hypogonadism, where the testes themselves cannot produce testosterone despite adequate or elevated LH and FSH, does not respond to enclomiphene or any SERM. Confirming that a patient's hypogonadism is secondary, not primary, is the first and most consequential step before considering this drug.

What the phase III evidence plausibly shows, and what still needs verification

The manufacturer of enclomiphene (marketed during development as Androxal) conducted phase III trials in men with secondary hypogonadism before the FDA issued a Complete Response Letter rather than an approval. Publicly available accounts describe the rejection as related to analytical chemistry and bioequivalence issues rather than a finding that the drug was unsafe or ineffective, but the exact regulatory rationale and trial-level statistics (specific percentages of men reaching target testosterone levels, exact adverse event rates, exact sample sizes) come from manufacturer conference abstracts and secondary reporting that this draft cannot independently verify against a primary, retrievable source. Editors should confirm these figures against the original trial registrations or peer-reviewed publications before they are presented to readers as precise numbers.

What can be stated with more confidence, based on the general pharmacology of SERMs and the mechanism of action:

• Enclomiphene's antagonism of hypothalamic estrogen receptors is expected to raise LH and FSH, and through that pathway, testosterone. This is a class-consistent, mechanistically supported effect, not a novel or contested claim.
• Because it raises testosterone through increased intratesticular signaling rather than suppressing the axis, it is expected to preserve or improve sperm concentration, in contrast to exogenous testosterone therapy, which reliably suppresses LH, FSH, and sperm production within months.
• Reported adverse effects in the trial program are generally described as mild (headache, hot flushes, nasopharyngitis) with low discontinuation rates, but exact percentages require verification.

Because zuclomiphene, the isomer excluded from enclomiphene, is the isomer most associated with the rare visual disturbances reported with clomiphene, enclomiphene is plausibly expected to carry a lower visual side-effect burden than clomiphene. This is a pharmacologically reasonable inference rather than a confirmed head-to-head finding from a source this draft can verify.

Evidence boundary: what is established, what is plausible, what is not established

Established: Enclomiphene has no FDA-approved indication. Clomiphene citrate is FDA-approved only for female ovulation induction. Testosterone replacement therapy suppresses gonadotropins and commonly impairs spermatogenesis. SERMs mechanistically increase LH/FSH by blocking hypothalamic estrogen feedback.

Plausible but not confirmed by a source this draft can verify: Specific percentages of men reaching a defined testosterone target on enclomiphene at 12.5 mg versus 25 mg; exact rates of hematocrit rise, hepatic enzyme elevation, or discontinuation in the phase III program; the precise regulatory reasoning behind the FDA's decision not to approve Androxal.

Not established: Long-term cardiovascular outcomes on enclomiphene; effects on bone mineral density with direct measurement; safety in men with a personal history of venous thromboembolism, given trial sample sizes too small to detect an uncommon signal; consistent potency and purity across compounding pharmacies, since no standardized manufacturing exists.

Baseline evaluation before starting

A defensible workup, drawn from general endocrine practice for evaluating male hypogonadism rather than an enclomiphene-specific label (none exists), includes:

• Two morning total testosterone measurements, ideally drawn 7 to 10 a.m., confirming a low value
• Free testosterone, LH, FSH, estradiol, prolactin, and SHBG, to confirm the pattern is secondary (low/normal LH and FSH with low testosterone) rather than primary
• Complete blood count with hematocrit, comprehensive metabolic panel, and fasting lipids
• PSA, with urological referral if elevated, consistent with general practice guidance for any intervention expected to raise testosterone in men
• Pituitary imaging if prolactin is elevated or gonadotropins are unexpectedly low, to rule out a pituitary mass
• Baseline semen analysis if fertility preservation is a primary reason for choosing this drug over testosterone replacement

Monitoring after starting

A reasonable, front-loaded monitoring cadence, adapted from general practice for hormone therapy monitoring in men (the Endocrine Society and American Urological Association publish guidance on testosterone therapy monitoring cadence, though written for exogenous testosterone rather than SERMs):

• 4 to 6 weeks: repeat total and free testosterone, LH, FSH, and estradiol. Rising LH and FSH alongside testosterone confirms the SERM mechanism is active. If gonadotropins fail to rise, reconsider whether the diagnosis is truly secondary hypogonadism.
• 3 months: repeat hormonal panel, add CBC (hematocrit) and hepatic transaminases.
• 6 and 12 months, then annually: full hormonal panel, CBC, metabolic panel, lipids, PSA. Semen analysis periodically if fertility preservation is the goal.

Testosterone itself, however produced, can raise hematocrit through erythropoietin stimulation. A hematocrit persistently above roughly 52 to 54 percent, the threshold generally used in testosterone therapy guidelines, should prompt dose reduction or discontinuation discussion; exact universal cutoffs for SERM-driven testosterone increases have not been separately established and are extrapolated from exogenous testosterone guidance.

Estradiol: the monitoring issue that is different with a SERM

Exogenous testosterone suppresses LH and FSH, which lowers intratesticular testosterone and testicular aromatization. Enclomiphene does the opposite: it raises intratesticular testosterone, and aromatase converts some of that testosterone to estradiol. Men with higher body fat, which correlates with greater aromatase activity, are more likely to see estradiol rise into a range associated with gynecomastia, fluid retention, or mood changes. Routine co-prescription of an aromatase inhibitor is not endorsed by mainstream endocrine guidance and is not without cost: suppressing estrogen in men accelerates bone loss, so any aromatase inhibitor added to manage estradiol should come with its own bone density monitoring plan, not just symptom tracking.

The compounding problem is a safety issue, not a footnote

Because no FDA-approved, manufactured enclomiphene product exists as of this writing (2026), every prescription is compounded. This means potency, purity, and the presence of contaminants (including inadvertent zuclomiphene carryover) depend entirely on the individual pharmacy's manufacturing standards. The FDA maintains an ongoing evaluation of substances used in compounding under sections 503A and 503B (FDA compounding bulk drug substances guidance), and clinicians prescribing compounded enclomiphene should confirm the pharmacy provides a certificate of analysis and holds current state licensure. A patient whose response changes unexpectedly after months of stability should prompt a question about whether the compounding source changed, not an assumption that the patient's physiology shifted.

Who should not receive enclomiphene, and when urgent evaluation is needed

Men with primary (testicular) hypogonadism, confirmed by elevated LH and FSH with low testosterone, will not respond to a SERM. Men with a personal history of venous or arterial thromboembolism, active liver disease, a pituitary macroadenoma, or a hormone-sensitive malignancy such as prostate or male breast cancer were excluded from the trial program and should not be started on this drug outside specialist input. New visual disturbance, jaundice, right upper quadrant pain, calf swelling and pain, or chest pain and shortness of breath in a patient on enclomiphene warrant urgent medical evaluation rather than waiting for the next scheduled lab check.

Decision framework: enclomiphene, testosterone replacement, or neither

Frequently asked questions this evidence can actually answer